понедельник, 11 апреля 2016 г.

Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital

Ligand Pharmaceuticals Inc. (LGND) Stock Rating Reaffirmed by Roth Capital


's stock had its "buy" rating restated by equities research analysts at Roth Capital in a research report issued to clients and investors on Saturday, MarketBeat reports. Other hedge funds have made changes to their positions in the company.



from Biotech News